The feasibility of selecting cord blood (CB) units at high-resolution HLA match has not been investigated. We analyzed the high-resolution donor-recipient HLA match of 100 double-unit 4-6/6 HLA-A,-B antigen, -DRB1 allele-matched CB grafts (units 1a and 1b) and their back-up units (n = 377 units in total). The median cryopreserved graft dose was 2.9 × 10 7 /kg/unit, and at high resolution these units had a median donor-recipient HLA-allele match of 5/8 (range 2-8/8) and 6/10 (range 2-9/10), respectively. We then evaluated how often use of high-resolution HLA-match criteria would change the original graft selection to substitute one or both of the back-up units for units 1a and/or 1b. On using a model in which both a higher eight-allele HLA match and a cell dose ⩾ 2.0 × 10 7 /kg/unit were required, graft selection changed in 33% of transplants with minimal effect on cell dose (8.3% reduction). In summary, while units chosen based on HLA-A,-B antigen and -DRB1 allele match have substantial mismatch at higher resolution, CB selection based on high-resolution HLA match is possible in a significant proportion of patients without compromise in cell dose.
INTRODUCTION
Unrelated donor cord blood (CB) is increasingly used as an alternative hematopoietic stem cell source in patients without suitable adult donors. Given the delayed engraftment but reduced GVHD incidence for the degree of HLA mismatch associated with CB transplantation (CBT), total nucleated cell (TNC) dose has traditionally taken priority in unit selection. HLA-match requirement has been less stringent (intermediate level resolution for HLA-A,-B antigens and high resolution for HLA-DRB1 alleles) with 0-2 mismatches allowed. While initial reports found no association between HLA-A,-B,-C,-DR,-DQ allele match and either grade II-IV acute GVHD or 2-year survival after single-unit CBT, 1 in a larger series Kurtzberg et al. 2 reported increased grade II-IV and III-IV acute GVHD in single-unit CBT recipients o5/6 HLA-A,-B,-DRB1 allele matched. 2 A significant association between intermediateresolution HLA-C mismatch and TRM risk has been reported in single-unit CBT recipients. 3 More recently, a 1568 patient registry series of single-unit CBT recipients has reported progressively increasing TRM with increasing HLA-allele mismatch ranging from 9% in recipients of eight-allele matched units to 41% in recipients of five-allele mismatched units, with this effect being independent of cell dose and patient age. 4 Our group has also demonstrated a decreased day-180 grade III-IV acute GVHD incidence if the donor-recipient HLA match of the engrafting unit of a double-unit pair was ⩾ 4/6 HLA-A,-B,-DRB1 alleles. 5 While comparable disease-free survival has been observed after single-unit CBT (children) or double-unit CBT (adults) and volunteer donor hematopoietic stem cell transplantation using current unit selection criteria, [6] [7] [8] [9] [10] [11] taken together the emerging data suggest that allele-level HLA matching should now be considered in both single-unit and double-unit CBT. However, the extent of HLA-allele mismatch of the CB grafts currently used has not been widely appreciated, and how to select CB units using high-resolution HLA matching has not been studied. The aims of this analysis were to examine the extent of allele-level HLA mismatch of 100 double-unit CB grafts transplanted at Memorial Sloan-Kettering Cancer Center (MSKCC), and to assess the feasibility of CB graft selection if high-resolution HLA-allele matching was required. During the period of the study, unit selection (units 1a, 1b and 1-2 back-up units) was based on 4-6/6 HLA-A,-B antigen, -DRB1 allele donor-recipient HLA-match, cryopreserved TNC dose ⩾ 1.5 (increased to ⩾ 2.0 × 10 7 /kg/unit in 2011), and the bank of origin as previously described.
MATERIALS AND METHODS
12,13 HLA match was usually given priority over TNC dose above the TNC dose threshold. The bank of origin was considered according to the MSKCC experience with that bank from the standpoint of post-thaw CD34+ cell viability as well as other factors such as reliability of information provided and processing method. RBC-depleted units were given priority over RBC-replete units, and other factors such as availability of attached segments for identity testing were considered mandatory. The vector of mismatch was considered in unit selection, with preference given to units with a unidirectional mismatch in the GVHD direction over units that had either bidirectional mismatch or mismatch in the direction of rejection only, 14 but the unit-unit HLA match was not. Following MSKCC policy, after initial review of all potential 4-6/6 matched CB units for a patient, up to 6-8 units were selected, from which 2 units were chosen for the graft (assigned as units 1a and 1b). Additionally, 1-2 back-up units were chosen in case of problems with shipping, thaw, low post-thaw CD34+ cell viability or graft failure, as previously reported. 13 Back-up units were the next best from the stand-point of dose and HLA match, but were always from domestic banks to permit shipment at short notice. While selected units were typed at HLA-A,-B,-C,-DRB1,-DQ alleles, high-resolution HLA match at loci other than HLA-DRB1 was not used in graft selection.
RESULTS

Extent of HLA mismatch at high resolution
We evaluated 377 CB units: 200 were used as double-unit grafts (units 1a and 1b) and 177 were back-up units (77 patients had 2 back-up units and 23 had one). The median cryopreserved TNC dose of the originally selected graft (units 1a and 1b) was 2.9 × 10 7 /kg/unit (range 1.5-17.8). At high resolution their median donor-recipient HLA match at HLA-A,-B,-DRB1 alleles was 4/6 (range 1-6/6). For 8 alleles (including HLA-C) it was 5/8 (range 2-8/8), and for 10 alleles (including HLA-C and -DQ) it was 6/10 (range 2-9/10). The median eight-allele HLA-match of units 1a and 1b was not different in 46 European (n = 92 units) and 54 nonEuropean (n = 108 units) CBT recipients: 5/8 (range 2-8/8) in both groups. However, non-Europeans received units with a greater mismatch at 10 HLA alleles (median 6/10, range 2-9) than Europeans (7/10, range 3-9), P = 0.001. The overall distribution of the original 4-6/6 HLA-A,-B antigen, -DRB1 allele-matched CB grafts at 8 HLA alleles, the new recommended standard in CBT, 4 is shown in Figure 1 . While '6/6' matched units were at least 5/8 HLA-allele matched, '5/6' units were as low as 3/8 matched, and '4/6' units were as low as 2/8 matched to the recipient.
Modeling the feasibility of unit selection using high-resolution HLA match We then evaluated how often the use of higher-resolution HLA-match criteria would have changed the original graft selection to substitute units 1a and/or 1b with one or both of the back-up units ('new graft selection'), and the effect on the TNC dose ( Table 1 ). The new graft required both a better allele-level HLA match and a cryopreserved TNC ⩾ 2.0 × 10 7 /kg/unit. Using this model, the graft would have changed in 33/100 (33%) transplants for the eight-allele HLA match. While the median HLA-match improvement was one allele, it ranged up to four alleles. Comparing the median TNC dose of the original graft and the new choice, an 8.3% and 8.5% graft TNC dose reduction was seen at 8 and 10 allele HLA-match grades, respectively. Thus, in grafts in which the unit selection changed, the effect on graft TNC dose of selecting units based on optimal high-resolution HLA match was modest. Of the 33 patients whose graft would have changed, 15 had non-European ancestry, indicating that improved matching was possible even in minority patients.
DISCUSSION
How to select CB units based on HLA-allele match is not established. We demonstrate that CB units routinely chosen for transplantation based on donor-recipient HLA-A,-B antigen, -DRB1 allele match have substantial disparity with the recipient when typed at HLA-A,-B,-C,-DRB1,-DQB1 alleles with units as low as 3/10 HLA-allele match being transplanted in patients of European ancestry and 2/10 HLA match in those of non-European backgrounds. Moreover, the adoption of higher HLA-match criteria is feasible and will frequently change the selection of the 'optimal' graft. Modeling the feasibility of such an approach in 100 recent 6/6 CBU N=10 10% 20% 50% 20% 5/6 CBU N=94 3% 12% 29% 34% 22% 4/6 CBU N=96 6% 25% 34% 31% 3% 0%
8 Allele Donor-Recipient HLA-Match Number of CB Units (CBU) Abbreviations: CB = cord blood; TNC = total nucleated cell. transplants, we found this can be achieved without significant compromise of TNC dose in approximately one-third of patients if the eight-allele HLA match is considered. This is highly relevant given the recent publication by Eapen et al. that suggests HLA matching at eight HLA alleles should now be considered a new standard in CBT as improved HLA match at eight HLA alleles mitigates TRM. 4 We limited our evaluation to the CB units originally selected as the best by standard criteria. However, if more units were considered, with increasing public inventory size it is likely that more patients could have had access to an even better matched unit with adequate TNC, especially in smaller children. While performing confirmatory HLA typing at high resolution could add cost to the search, the current CBT standard is to type HLA-DRB1 at high resolution, and the increase associated with upgrading HLA-A,-B,-C from intermediate to high resolution is modest (~$500 US). Furthermore, with current improvements in HLA methodologies, some banks are now typing CB units at the allele level, and this information will assist in future CB graft selection.
The recent Eapen analysis recommends that units with less than 4/8 HLA-allele match not be used. 4 However, how to trade off cell dose against high-resolution HLA match in patients whose best units are o 3 ×10 7 /kg (the recommended lower limit of cryopreserved TNC dose in this analysis 4 ) is not established, and will likely become even more complex when cell dose is evaluated by CD34+ cells and not TNC dose. The lower limit of acceptable HLA match at high resolution also requires further investigation and the comparison of transplantation results with CB units with a high degree of mismatch vs alternative treatment approaches such as transplantation with mismatched unrelated or haploidentical donors is warranted. Whether there is any disadvantage to fully matched CB units in the setting of hematologic malignancies also remains highly controversial. The impact of allele-level HLA mismatch at different loci is also unknown and, therefore, at this time we consider mismatches at any of the HLA-A,-B,-C,-DRB1 loci equally.
In approximately two-thirds of patients in this analysis the graft choice did not change. Nonetheless, our findings have practical implications for unit selection for both single-unit and double-unit CBT. In this study, only the two backup units were considered for potential substitution of either unit of the graft as they reflected the 3rd and 4th best units by the standards employed during the period of the study. If additional units were considered beyond the best four units it is possible that the percentage of grafts that would have changed would have increased. Additionally, we also agree that as the global inventory of quality units increases the number of units that are optimal from the standpoint of highresolution HLA match and cell dose will likely increase. In the interim, this study suggests that high-resolution HLA matching could be implemented in a significant proportion of patients of both European and non-European ancestry. This finding has special significance for children of low weight in whom the TNC dose is less limiting and thus unit selection based on highresolution HLA match is more feasible.
